Chadi Nabhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chadi Nabhan has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Sonali M. Smith
A The University of Chicago Medical Center , Chicago , IL , USA
4 shared publicationsAndrew D. Zelenetz
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
2 shared publications- Andrew M. Evens
Rutgers Cancer Institute, New Brunswick, NJ
2 shared publications Brian C.-H. Chiu
Department of Health Studies, University of Chicago, Chicago, IL, USA
2 shared publications- Brian K. Link
Division of Hematology, Oncology, and Bone and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA
2 shared publications Christopher R. Flowers
Winship Cancer Institute, Emory University, Georgia
2 shared publications
Latest Publications
- 14 July 2016
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 58 (3) , 752-753
Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma
Despite recent advances, management of relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) remains a clinical challenge. While hematopoietic stem cell transplantation (HSCT) provides t...
- 14 July 2016
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 58 (3) , 752-753
Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma
Despite recent advances, management of relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) remains a clinical challenge. While hematopoietic stem cell transplantation (HSCT) provides t...
- Open Access
- 28 April 2016
- Published by Wiley in American Journal of Hematology
- Vol. 91 (8) , 770-775
Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States
We aimed to comprehensively study sex differences in disease and patients' characteristics, treatment and outcomes in patients with follicular lymphoma (FL) in the United States (USA) utilizing the National LymphoCare Study registry (2004–2014). Among evaluable males (n = 1277) and females (n = 1375) with FL, females less commonly received anthracyclines and were more likely to receive rituximab monotherapy. Overall response rates were comparable between sex groups. With a median follow‐up of 8.1 years, male sex emerged as an adverse factor for PFS (HR, 0.84, 95% CI, 0.72–0.97). Lymphoma‐related mortality (HR, 0.46; 0.23–0.93) and overall survival (HR, 0.63; 0.41–0.97) favored females aged ≤60 years. There are subtle differences in outcomes between male and female FL patients diagnosed and treated in the contemporary era. These data represent the largest prospective analysis of FL patients in the USA based on sex and can aid design of clinical trials for this disease. Am. J. Hematol. 91:770–775, 2016.
- 28 April 2016
- Published by Wiley in American Journal of Hematology
- Vol. 91 (8) , 770-775
Open AccessDisease, treatment, and outcome differences between men and women with follicular lymphoma in the United States
We aimed to comprehensively study sex differences in disease and patients' characteristics, treatment and outcomes in patients with follicular lymphoma (FL) in the United States (USA) utilizing the National LymphoCare Study registry (2004–2014). Among evaluable males (n = 1277) and females (n = 1375) with FL, females less commonly received anthracyclines and were more likely to receive rituximab monotherapy. Overall response rates were comparable between sex groups. With a median follow‐up of 8.1 years, male sex emerged as an adverse factor for PFS (HR, 0.84, 95% CI, 0.72–0.97). Lymphoma‐related mortality (HR, 0.46; 0.23–0.93) and overall survival (HR, 0.63; 0.41–0.97) favored females aged ≤60 years. There are subtle differences in outcomes between male and female FL patients diagnosed and treated in the contemporary era. These data represent the largest prospective analysis of FL patients in the USA based on sex and can aid design of clinical trials for this disease. Am. J. Hematol. 91:770–775, 2016.
- 8 October 2015
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 10 (4) , 448-455
The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project
Peripheral T cell lymphomas (PTCLs) are a heterogeneous group of lymphoid malignancies that portend a poor prognosis and have an undefined optimal therapeutic strategy. Data on best practices stem from prior studies that have generally included B cell lymphomas. However, the enhanced ability to diagnose PTCLs, the development of newer agents specific for PTCLs, and its increased incidence have called the scientific community to develop better strategies to combat these neoplasms. To that end, T cell lymphoma registries were developed in an attempt to answer relevant questions on the prognosis and management of PTCLs. The largest registries currently enrolling patients are the Comprehesive Oncology Measures for PeripheraL T-cEll Lymphoma TrEatment (COMPLETE) and the T-Cell Project. Despite the inherent limitations of these studies, valuable information are being collected to refine our management approaches and to aid in designing future clinical trials. This review illustrates the value of these registries and describes the critical questions that need to be answered.
- 8 October 2015
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 10 (4) , 448-455
The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project
Peripheral T cell lymphomas (PTCLs) are a heterogeneous group of lymphoid malignancies that portend a poor prognosis and have an undefined optimal therapeutic strategy. Data on best practices stem from prior studies that have generally included B cell lymphomas. However, the enhanced ability to diagnose PTCLs, the development of newer agents specific for PTCLs, and its increased incidence have called the scientific community to develop better strategies to combat these neoplasms. To that end, T cell lymphoma registries were developed in an attempt to answer relevant questions on the prognosis and management of PTCLs. The largest registries currently enrolling patients are the Comprehesive Oncology Measures for PeripheraL T-cEll Lymphoma TrEatment (COMPLETE) and the T-Cell Project. Despite the inherent limitations of these studies, valuable information are being collected to refine our management approaches and to aid in designing future clinical trials. This review illustrates the value of these registries and describes the critical questions that need to be answered.
- 1 October 2015
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 1 (7) , 965-974
Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era
Review from JAMA Oncology — Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era
- 1 October 2015
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 1 (7) , 965-974
Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era
Review from JAMA Oncology — Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era
- Open Access
- 7 April 2015
- Published by Wiley in British Journal of Haematology
- Vol. 170 (1) , 85-95
Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma‐related mortality in elderly follicular lymphoma in the United States
Summary: Data from the National LymphoCare Study (a prospective, multicentre registry that enrolled follicular lymphoma (FL) patients from 2004 to 2007) were used to determine disease characteristics, treatment patterns, outcomes and prognosis for elderly FL (eFL) patients. Of 2650 FL patients, 209 (8%) were aged >80 years; these eFL patients more commonly had grade 3 disease, less frequently received chemoimmunotherapy and anthracyclines, and had lower response rates when compared to younger patients. With a median follow‐up of 6.9 years, 5‐year overall survival (OS) for eFL patients was 59%; 38% of deaths were lymphoma‐related. No treatment produced superior OS among eFL patients. In multivariate Cox models, anaemia, B‐symptoms and male sex predicted worse OS (P < 0·01); a prognostic index of these factors (0, 1 or ≥2 present) predicted OS [hazard ratio (95% CI): ≥2 vs. 0, 4·72 (2·38–9·33); 1 vs. 0, 2·63 (1·39–4·98)], with a higher concordance index (0·63) versus the Follicular Lymphoma International Prognostic Index (0·55). The index was validated in an independent cohort. In the largest prospective US‐based eFL cohort, no optimal therapy was identified and nearly 40% of deaths were lymphoma‐related, representing baseline outcomes in the modern era.
- 7 April 2015
- Published by Wiley in British Journal of Haematology
- Vol. 170 (1) , 85-95
Open AccessDisease characteristics, treatment patterns, prognosis, outcomes and lymphoma‐related mortality in elderly follicular lymphoma in the United States
Summary: Data from the National LymphoCare Study (a prospective, multicentre registry that enrolled follicular lymphoma (FL) patients from 2004 to 2007) were used to determine disease characteristics, treatment patterns, outcomes and prognosis for elderly FL (eFL) patients. Of 2650 FL patients, 209 (8%) were aged >80 years; these eFL patients more commonly had grade 3 disease, less frequently received chemoimmunotherapy and anthracyclines, and had lower response rates when compared to younger patients. With a median follow‐up of 6.9 years, 5‐year overall survival (OS) for eFL patients was 59%; 38% of deaths were lymphoma‐related. No treatment produced superior OS among eFL patients. In multivariate Cox models, anaemia, B‐symptoms and male sex predicted worse OS (P < 0·01); a prognostic index of these factors (0, 1 or ≥2 present) predicted OS [hazard ratio (95% CI): ≥2 vs. 0, 4·72 (2·38–9·33); 1 vs. 0, 2·63 (1·39–4·98)], with a higher concordance index (0·63) versus the Follicular Lymphoma International Prognostic Index (0·55). The index was validated in an independent cohort. In the largest prospective US‐based eFL cohort, no optimal therapy was identified and nearly 40% of deaths were lymphoma‐related, representing baseline outcomes in the modern era.
- 3 April 2014
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 55 (12) , 2778-2784
The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the modern era
To analyze racial, ethnic, sex and age disparities in chronic lymphocytic leukemia (CLL), we examined population-based overall survival (OS) data from Surveillance, Epidemiology, and End Results (SEER)-13 (1992–2009) across various races/ethnicities over two consecutive 9-year periods: era 1 (1992–2000) and era 2 (2001–2009). We analyzed 28 590 patients (whites: 24 438, blacks: 1954, Hispanics: 1389 and Asians/Pacific Islanders [A/PI]: 809). A higher proportion of whites were aged > 80 years (22% vs. 17% [Hispanics], 16% [blacks], 16% [A/PI]; p < 0.001). Higher socioeconomic status (SES) was also identified for A/PI and whites compared with blacks and Hispanics (p < 0.001). OS for all patients improved at 5 years (66% vs. 60%, p < 0.0001) and was significant in all races/ethnicities except A/PI. Patients of higher SES had better outcomes than others independent of era, but both SES classes experienced relative improvement in their OS across eras. The OS of patients with CLL has improved in the modern era but racial/ethnic, gender and SES differences persist, warranting further investigation.
- 3 April 2014
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 55 (12) , 2778-2784
The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the modern era
To analyze racial, ethnic, sex and age disparities in chronic lymphocytic leukemia (CLL), we examined population-based overall survival (OS) data from Surveillance, Epidemiology, and End Results (SEER)-13 (1992–2009) across various races/ethnicities over two consecutive 9-year periods: era 1 (1992–2000) and era 2 (2001–2009). We analyzed 28 590 patients (whites: 24 438, blacks: 1954, Hispanics: 1389 and Asians/Pacific Islanders [A/PI]: 809). A higher proportion of whites were aged > 80 years (22% vs. 17% [Hispanics], 16% [blacks], 16% [A/PI]; p < 0.001). Higher socioeconomic status (SES) was also identified for A/PI and whites compared with blacks and Hispanics (p < 0.001). OS for all patients improved at 5 years (66% vs. 60%, p < 0.0001) and was significant in all races/ethnicities except A/PI. Patients of higher SES had better outcomes than others independent of era, but both SES classes experienced relative improvement in their OS across eras. The OS of patients with CLL has improved in the modern era but racial/ethnic, gender and SES differences persist, warranting further investigation.
- 1 April 2014
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 12 (2) , 100-105
Role of Sorafenib in Overcoming Resistance of Chemotherapy-Failure Castration-Resistant Prostate Cancer
- 1 April 2014
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 12 (2) , 100-105
Role of Sorafenib in Overcoming Resistance of Chemotherapy-Failure Castration-Resistant Prostate Cancer
- Open Access
- 14 March 2014
- Published by Wiley in American Journal of Hematology
- Vol. 89 (6) , 633-638
The impact of race, age, and sex in follicular lymphoma: A comprehensive SEER analysis across consecutive treatment eras
The impact of race/ethnicity and the additional factors of age, sex, and socioeconomic status (SES) on follicular lymphoma (FL) outcomes have not been comprehensively studied and are not well defined. We examined population‐based FL data from >18,000 patients in SEER‐13 (1992–2009) investigating race/ethnicity and the impact of relevant factors including sex, age, and SES. Further, we compared data over two consecutive periods: Era‐1 (1992–2000, n = 8,355) and Era‐2 (2001–2009, n = 10,475). We identified 18,830 FL patients (White: n = 15,116; Hispanic: n = 1,627; Asian/Pacific Islander (A/PI): n = 1,002; and Black: n = 846). Median ages (years) differed significantly by race/ethnicity: White: 62.1, Hispanic: 57.3, A/PI: 60.7, and Black: 56.8 (P < 0.01 each race versus White). Overall survival (OS) was superior in Era‐2 versus Era‐1 for all patients (5‐year: 76.7% versus 67.4%, respectively, P < 0.001). Further, survival was significantly improved for all age groups P = 0.0019), and females (P < 0.001) across eras. Females had superior OS compared with males in Era‐1 (P = 0.004), but not in Era‐2. Additionally, all races, except A/PI, had improved 5‐year OS rates from Era‐1 to Era‐2. Finally, OS improved across eras for lower and higher SES populations; however those with higher SES were superior to lower SES patients in both eras. In conclusion, and in the largest comprehensive evaluation of US‐based FL patients to date, we show that despite improvements in OS for FL over time, critical disparities across races/ethnicities, sex, and age groups remain in the modern era and warrant further studies. Am. J. Hematol. 89:633–638, 2014.
- 14 March 2014
- Published by Wiley in American Journal of Hematology
- Vol. 89 (6) , 633-638
Open AccessThe impact of race, age, and sex in follicular lymphoma: A comprehensive SEER analysis across consecutive treatment eras
The impact of race/ethnicity and the additional factors of age, sex, and socioeconomic status (SES) on follicular lymphoma (FL) outcomes have not been comprehensively studied and are not well defined. We examined population‐based FL data from >18,000 patients in SEER‐13 (1992–2009) investigating race/ethnicity and the impact of relevant factors including sex, age, and SES. Further, we compared data over two consecutive periods: Era‐1 (1992–2000, n = 8,355) and Era‐2 (2001–2009, n = 10,475). We identified 18,830 FL patients (White: n = 15,116; Hispanic: n = 1,627; Asian/Pacific Islander (A/PI): n = 1,002; and Black: n = 846). Median ages (years) differed significantly by race/ethnicity: White: 62.1, Hispanic: 57.3, A/PI: 60.7, and Black: 56.8 (P < 0.01 each race versus White). Overall survival (OS) was superior in Era‐2 versus Era‐1 for all patients (5‐year: 76.7% versus 67.4%, respectively, P < 0.001). Further, survival was significantly improved for all age groups P = 0.0019), and females (P < 0.001) across eras. Females had superior OS compared with males in Era‐1 (P = 0.004), but not in Era‐2. Additionally, all races, except A/PI, had improved 5‐year OS rates from Era‐1 to Era‐2. Finally, OS improved across eras for lower and higher SES populations; however those with higher SES were superior to lower SES patients in both eras. In conclusion, and in the largest comprehensive evaluation of US‐based FL patients to date, we show that despite improvements in OS for FL over time, critical disparities across races/ethnicities, sex, and age groups remain in the modern era and warrant further studies. Am. J. Hematol. 89:633–638, 2014.
- 1 March 2014
- Published by Elsevier in Leukemia Research
- Vol. 38 (3) , 299-303
Extramedullary chronic lymphocytic leukemia: Systematic analysis of cases reported between 1975 and 2012
- 1 March 2014
- Published by Elsevier in Leukemia Research
- Vol. 38 (3) , 299-303
Extramedullary chronic lymphocytic leukemia: Systematic analysis of cases reported between 1975 and 2012
- 1 February 2014
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 12 (1) , 27-32
Lenalidomide Monotherapy in Chemotherapy-Naive, Castration-Resistant Prostate Cancer Patients: Final Results of a Phase II Study
- 1 February 2014
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 12 (1) , 27-32
Lenalidomide Monotherapy in Chemotherapy-Naive, Castration-Resistant Prostate Cancer Patients: Final Results of a Phase II Study